苏州丰倍生物科技股份有限公司 首次公开发行股票并在主板上市发行安排及初步询价公告

Group 1 - The company, Suzhou Fengbei Biotechnology Co., Ltd., is set to conduct its initial public offering (IPO) and list on the Shanghai Stock Exchange, with the approval from the China Securities Regulatory Commission [1][17] - The IPO will involve a combination of strategic placement, offline issuance, and online issuance, organized by the lead underwriter, Guotai Haitong Securities [2][17] - The total number of shares to be publicly issued is 35.9 million, accounting for 25.02% of the total share capital post-issuance [17][18] Group 2 - The strategic placement will initially consist of 7.18 million shares, representing 20% of the total issuance, with adjustments based on the allocation mechanism [18] - The offline issuance will initially account for 17.23 million shares, which is 60% of the remaining shares after the strategic placement [18] - The online issuance will consist of 11.49 million shares, making up 40% of the remaining shares after the strategic placement [18] Group 3 - The pricing for the IPO will be determined through preliminary inquiries from qualified investors, considering various factors such as company profitability and comparable company valuations [19] - The company will implement a lock-up period for 10% of the shares allocated to offline investors, lasting six months from the date of listing [20][13] - The online issuance shares will have no restrictions and will be tradable immediately upon listing [20]